{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:35:05Z","timestamp":1793313305187,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In the US, the overdose crisis continues to be driven by fentanyl, xylazine, and stimulant-involved polysubstance use among people who inject drugs, especially those who are not engaged in medical care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the overall prevalence of illicit drugs detected among people who inject drugs in 5 US cities by city and sociodemographic characteristics and assess trends in drug detection over a 2-year period.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study included data from individuals enrolled in HIV Prevention Trials Network (HPTN) 094, a randomized clinical trial to evaluate an integrated mobile unit engaging adults aged 18 years or older who inject drugs in HIV services between June 2021 and September 2023 in New York City; Houston, Texas; Los Angeles, California; Philadelphia, Pennsylvania; and Washington, DC. All analyses were completed between August 2021 and August 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Baseline prevalence of toxicologic detection was assessed using liquid chromatography\u2013high-resolution mass spectrometry. Differences in toxicologic detection by sociodemographic characteristics (age, race and ethnicity, housing status, and incarceration history), study site, and illicit drug type over time were analyzed using generalized linear models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Across 444 participants, 303 (68.2%) were male, 267 (60.1%) were aged 30 to 49 years, 203 of 440 (46.1%) were unhoused, and 91 of 442 (20.6%) had a recent incarceration history. In all, 414 participants (93.2%) tested positive for fentanyl, 328 (73.9%) for cocaine, 299 (67.3%) for amphetamine-type stimulants, and 234 (52.7%) for xylazine. Nearly all participants (421 [94.8%]) tested positive for polysubstance drugs (fentanyl or opioids with stimulants, benzodiazepines, cocaine, and\/or xylazine). Fentanyl detection was high across all sites; xylazine was most common in New York City (68 of 94 [72.3%]), Philadelphia (111 of 112 [99.1%]), and Washington, DC (31 of 41 [75.6%]). Every 6 months, xylazine detection increased in New York City by 10.3% (95% CI, 4.0%-16.5%;\n P<\/jats:italic>\n \u2009=\u2009.001), and its prevalence stayed high in Philadelphia. Amphetamine-type stimulant detection increased in Washington, DC, by 15.0% (95% CI, 2.9%-27.1%) every 6 months over the enrollment period (\n P<\/jats:italic>\n \u2009=\u2009.02). Across all sites, cocaine prevalence was higher among unhoused than housed participants (difference, 11.4%; 95% CI, 3.6%-19.2%;\n P<\/jats:italic>\n \u2009=\u2009.004), and stimulant detection was elevated among those recently incarcerated vs not (difference, 9.9%; 95% CI, 1.4%-18.5%;\n P<\/jats:italic>\n \u2009=\u2009.02).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cross-sectional study found widespread fentanyl and polysubstance detection, with rising xylazine and stimulant detection that varied by sociodemographic and structural vulnerabilities and may be due to adulteration within the unregulated drug supply. These findings highlight urgent public health needs for real-time drug supply surveillance, targeted harm-reduction services, and integrated treatment approaches to reduce overdose risk and address social and structural vulnerabilities.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.55882","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:30:33Z","timestamp":1770309033000},"page":"e2555882","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of Illicit Drug Detection in 5 US Cities Among Out-of-Treatment People Who Inject Drugs"],"prefix":"10.1001","volume":"9","author":[{"given":"Nabila","family":"El-Bassel","sequence":"first","affiliation":[{"name":"School of Social Work, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Skalland","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hanscom","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Fogel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Paul","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Denis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodman-Meza","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Lake","sequence":"additional","affiliation":[{"name":"UTHealth Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen A. B.","family":"Morrison","sequence":"additional","affiliation":[{"name":"ICAP, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayla","family":"Harris-Wisecarver","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Cummings","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redonna","family":"Chandler","sequence":"additional","affiliation":[{"name":"Addiction Policy Forum, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Andrew","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HPTN 094 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quiana","family":"Allen","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashaunna","family":"Redd","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Metzger","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usiel","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Magnus","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Siegel","sequence":"additional","affiliation":[{"name":"for the HPTN 094 Study Team"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"1","key":"zoi251486r1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","article-title":"Estimated number of people who inject drugs in the United States.","volume":"76","author":"Bradley","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi251486r2","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021.","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"issue":"1","key":"zoi251486r4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40352-025-00317-9","article-title":"Medication for opioid use disorder service delivery in carceral facilities: update and summary report.","volume":"13","author":"Berk","year":"2025","journal-title":"Health Justice"},{"issue":"9","key":"zoi251486r5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","article-title":"Meta-analysis of drug-related deaths soon after release from prison.","volume":"105","author":"Merrall","year":"2010","journal-title":"Addiction"},{"issue":"2","key":"zoi251486r6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014a high risk of death for former inmates.","volume":"356","author":"Binswanger","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi251486r7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"issue":"6","key":"zoi251486r8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1176\/ps.2009.60.6.842","article-title":"Validation of a brief screening instrument for identifying psychiatric disorders among newly incarcerated adults.","volume":"60","author":"Ford","year":"2009","journal-title":"Psychiatr Serv"},{"key":"zoi251486r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112585","article-title":"Association between homelessness and opioid overdose and opioid-related hospital admissions\/emergency department visits.","volume":"242","author":"Yamamoto","year":"2019","journal-title":"Soc Sci Med"},{"key":"zoi251486r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110910","article-title":"State-level homelessness and drug overdose mortality: evidence from US panel data.","volume":"250","author":"Cano","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi251486r11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1353\/hpu.2016.0075","article-title":"Characteristics of homeless adults who died of drug overdose: a retrospective record review.","volume":"27","author":"Bauer","year":"2016","journal-title":"J Health Care Poor Underserved"},{"issue":"4","key":"zoi251486r12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.ogx.0000446906.02266.3c","article-title":"Housing as health care: New York\u2019s boundary-crossing experiment.","volume":"69","author":"Doran","year":"2014","journal-title":"Obstet Gynecol Surv"},{"key":"zoi251486r13","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","article-title":"Infectious diseases and injection drug use: public health burden and response.","volume":"222","author":"Levitt","year":"2020","journal-title":"J Infect Dis"},{"key":"zoi251486r14","doi-asserted-by":"publisher","DOI":"10.2196\/49527","article-title":"Estimated number of injection-involved overdose deaths in US states from 2000 to 2020: secondary analysis of surveillance data.","volume":"10","author":"Hall","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"zoi251486r15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/00365549009027133","article-title":"Hepatitis C virus infection in intravenous drug users: prevalence and risk factors.","volume":"22","author":"Girardi","year":"1990","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"zoi251486r17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"zoi251486r19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13722-022-00322-5","article-title":"The Rural Opioid Initiative Consortium description: providing evidence to understand the fourth wave of the opioid crisis.","volume":"17","author":"Jenkins","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"zoi251486r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109003","article-title":"Transition from injecting opioids to smoking fentanyl in San Francisco, California.","volume":"227","author":"Kral","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi251486r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100163","article-title":"High levels of interest in access to free safer smoking equipment to reduce injection frequency among people who inject drugs in Seattle, Washington.","volume":"7","author":"Reid","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"zoi251486r22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13063-023-07899-5","article-title":"Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).","volume":"25","author":"Goodman-Meza","year":"2024","journal-title":"Trials"},{"issue":"9596","key":"zoi251486r23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"26","key":"zoi251486r25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.15585\/mmwr.mm7326a2","article-title":"Reported xylazine use among adults aged =18 years evaluated for substance use treatment\u2014United States, July 2022-September 2023.","volume":"73","author":"Jiang","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"zoi251486r26","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.15585\/mmwr.mm7037a4","article-title":"Notes from the field: xylazine detection and involvement in drug overdose deaths\u2014United States, 2019.","volume":"70","author":"Kariisa","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi251486r27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/anoc.12012","article-title":"\u201cWe\u2019re supposed to be asleep?\u201d vigilance, paranoia, and the alert methamphetamine user.","volume":"24","author":"McKenna","year":"2013","journal-title":"Anthropol Conscious"},{"issue":"3","key":"zoi251486r28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","article-title":"Drug checking services for people who use drugs: a systematic review.","volume":"117","author":"Maghsoudi","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"zoi251486r29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13722-024-00520-3","article-title":"Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.","volume":"19","author":"Perez-Brumer","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"zoi251486r30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13012-024-01363-x","article-title":"A data-driven approach to implementing the HPTN 094 complex intervention INTEGRA in local communities.","volume":"19","author":"Smith","year":"2024","journal-title":"Implement Sci"},{"key":"zoi251486r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108286","article-title":"Introducing NIDA\u2019s new national drug early warning system.","volume":"217","author":"Cottler","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi251486r3","doi-asserted-by":"crossref","unstructured":"Garnett? MF, Mini\u00f1o? AM. Drug overdose deaths in the United States, 2003-2023. National Center for Health Statistics data brief No. 522. December 2024. Accessed September 7, 2025. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db522.htm","DOI":"10.15620\/cdc\/174639"},{"key":"zoi251486r16","unstructured":"US overdose deaths decrease almost 27% in 2024. News release. National Center for Health Statistics, Centers for Disease Control and Prevention. May 14, 2025. Accessed September 7, 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/releases\/20250514.html"},{"key":"zoi251486r18","unstructured":"Centers for Disease Control and Prevention. Polysubstance overdose. May 8, 2024. Accessed September 6, 2025. https:\/\/www.cdc.gov\/overdose-prevention\/about\/polysubstance-overdose.html"},{"key":"zoi251486r24","unstructured":"US Drug Enforcement Administration. The growing threat of xylazine and its mixture with illicit drugs. October 2022. Accessed September 6, 2025. https:\/\/www.dea.gov\/sites\/default\/files\/2022-12\/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf"},{"key":"zoi251486r31","unstructured":"Shoptaw? S, El-Bassel? N, Andrew? P, . HPTN 094 Study Team. Preliminary efficacy for HPTN 094: 26-week RCT of integrated strategies for people who inject drugs. Presented at: Conference on Retroviruses and Opportunistic Infections; March 9-12, 2025; San Francisco, California. Accessed September 6, 2025. https:\/\/www.hptn.org\/sites\/default\/files\/inline-files\/HPTN%20094%20CROI%202025%20-%203-8-2025.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844669\/elbassel_2026_oi_251486_1769623257.44181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:30:34Z","timestamp":1770309034000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.55882","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}